Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

164014503

Full Text :

https://doi.org/10.1200/JCO.2023.41.16_suppl.6029